Lonza Expands Biologics Collaboration

Lonza Group, a leading contract development and manufacturing organization (CDMO), has announced an expanded strategic collaboration with a major US-based biopharmaceutical company. This expansion adds two biologics programs for commercial production, with an option for two more, and reinforces an existing multi-year relationship. The collaboration involves long-term commitments across a broad portfolio of biologics programs, supporting flexibility in demand and development risk. Lonza Group will leverage its US commercial-scale biologics sites and European capacities, along with its mammalian antibody technology and process optimization techniques, to provide end-to-end support. The partnership is projected to generate a cumulative multi-billion CHF value, underscoring Lonza Group's attractiveness as a manufacturing partner.